Niagen Bioscience Increases Share Repurchase Program to $20 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NAGE?
Niagen Bioscience announced that its board of directors has authorized an increase to the company's previously disclosed share repurchase program, raising the total authorization from $10M to $20M of the company's outstanding common stock. Through March 17, the company has repurchased approximately $2.6M of its common stock under the share repurchase program.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NAGE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NAGE
Wall Street analysts forecast NAGE stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.550
Low
12.00
Averages
16.33
High
23.00
Current: 4.550
Low
12.00
Averages
16.33
High
23.00
About NAGE
Niagen Bioscience, Inc. specializes in nicotinamide adenine dinucleotide (NAD+) science and healthy-aging research. At the center of its clinically proven product portfolio is Niagen (patented nicotinamide riboside or NR). Niagen powers its consumer supplement, Tru Niagen, a NAD+ boosting oral supplement in the United States, and Niagen Plus, featuring pharmaceutical-grade intravenous and injectable Niagen products. Its segments include Consumer Products, Ingredients, and Analytical Reference Standards and Services. Consumer Products segment provides finished dietary supplement products containing its proprietary ingredients directly to consumers and distributors, as well as NAD+ test kits exclusively to healthcare practitioners. Ingredients segment develops and commercializes proprietary-based ingredient technologies. Analytical Reference Standards and Services segment is focused on natural product fine chemicals, known as phytochemicals, and related research and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Niagen Bioscience Surpasses 300 Research Agreements, Strengthening NAD+ Research
- Research Agreement Milestone: Niagen Bioscience's external research program has surpassed 300 material transfer agreements (MTAs), marking its leading position in global NAD+ research support and is expected to further enhance the company's influence in the healthy aging sector.
- Clinical Research Outcomes: The program has contributed to the publication of 45 clinical studies, demonstrating the effectiveness and safety of Niagen as an NAD+ booster, thereby enhancing its credibility and competitive edge in the scientific community.
- International Collaboration Expansion: With agreements established with over 200 institutions across 34 countries, the growing global interest in NAD+ biology positions Niagen as a trusted NAD+ booster for researchers, promoting independence and rigor in scientific research.
- Future Research Directions: Niagen Bioscience plans to expand its research into areas such as topical applications and pharmaceutical-grade Niagen intravenous injections, aiming to meet the increasing interest in NAD+ biology and further explore its potential in health and aging.
See More
Niagen Bioscience Increases Share Repurchase Program to $20 Million
- Repurchase Program Expansion: Niagen Bioscience has increased its share repurchase program authorization from $10 million to $20 million, reflecting the company's confidence in its stock value, which is expected to enhance investor sentiment and potentially boost stock performance.
- Repurchase Progress: As of March 17, 2026, the company has repurchased approximately $2.6 million of its common stock under the program, indicating proactive measures to protect shareholder interests amid market fluctuations and reinforcing confidence in its financial health.
- Performance Beats Expectations: Niagen Bioscience reported a GAAP EPS of $0.05, beating estimates by $0.03, and revenue of $33.84 million, exceeding expectations by $2.14 million, demonstrating the company's ability to maintain strong growth in a competitive supplement market.
- Future Growth Targets: The company aims for a revenue growth of 10-15% by 2026 while expanding its injectable product line, indicating strategic decisions focused on product diversification and market share enhancement to further solidify its market position.
See More
Niagen Bioscience Expands Share Repurchase Program to $20 Million
- Program Expansion: Niagen Bioscience has increased its share repurchase program authorization from $10 million to $20 million, reflecting the company's strong confidence in its long-term strategy and value, which is expected to enhance market recognition of its stock.
- Repurchase Progress: As of March 17, 2026, the company has repurchased approximately $2.6 million of its common stock, indicating proactive measures taken to capitalize on market undervaluation, thereby strengthening investor trust.
- Flexibility in Repurchases: The repurchase program is authorized through October 31, 2027, allowing the company to execute buybacks flexibly based on market conditions, potentially through open market transactions or privately negotiated deals, enhancing capital management flexibility.
- Strategic Implications: CEO Rob Fried emphasized that the repurchase program not only reflects confidence in the company's fundamentals but also aims to leverage the disconnect in market valuation of NAGE, thereby creating long-term value for shareholders and further solidifying the company's market position.
See More
Niagen Bioscience to Participate in ROTH Conference
- Management Participation: Niagen Bioscience's senior management will attend the 2026 ROTH Conference, showcasing the company's leadership in healthy aging and likely attracting investor interest while enhancing brand visibility.
- CEO Panel Discussion: CEO Rob Fried will participate in the Technologies Advancing Healthy Aging panel on March 23, with the livestream broadening audience access to the company's innovations in NAD+ science, potentially fostering future investment opportunities.
- One-on-One Investor Meetings: Rob Fried and CFO Ozan Pamir will engage in face-to-face meetings with institutional investors, strengthening relationships with potential investors and driving company financing and market expansion.
- Industry Networking Platform: The conference will gather executives from numerous private and public companies, providing small group discussions and analyst-selected fireside chats, facilitating knowledge sharing and collaboration within the industry, thereby enhancing Niagen's influence in the sector.
See More
Niagen® Expands into Skincare Market with Innovative Product Launch
- Skincare Innovation Lab: Niagen Bioscience has launched the Niagen® Skincare Innovation Lab, aiming to translate its leadership in NAD+ science into skincare innovation, marking the company's entry into the $122.11 billion global skincare market.
- First Product Launch: The inaugural product, Niagen NanoCloud, utilizes a sealed, waterless format to ensure the stability of NAD+ ingredients until use, expected to significantly enhance skincare efficacy and meet consumer demand for effective products.
- Significant Market Potential: Market research indicates that the global anti-aging cosmetics market is projected to reach $106.98 billion by 2035, and Niagen's entry positions it well within the rapidly growing skincare sector, driving future product development.
- Positive Consumer Feedback: A study involving 37 female participants found that consistent use of Niagen NanoCloud resulted in visible skin improvements within two weeks, indicating the product's effectiveness in enhancing skin texture and hydration, thereby strengthening the brand's competitive position in the market.
See More
Niagen Bioscience Reports Q4 and Full-Year 2025 Financial Results
- Financial Performance Overview: Niagen Bioscience reported a Q4 net income of $4.1 million, or $0.05 per share, down from $7.2 million and $0.09 per share in the previous year, indicating challenges in profitability.
- Sales Growth Analysis: Total net sales for Q4 2025 reached $33.84 million, a 16% increase, while full-year sales grew by 30% to $129.4 million, reflecting strong market demand and operational effectiveness.
- Cash Flow Status: As of December 31, 2025, the company had cash and cash equivalents totaling $64.8 million, up from $44.7 million the previous year, enhancing financial stability and capacity for future investments.
- Future Outlook: For 2026, Niagen anticipates a net sales growth of 10-15%, primarily driven by e-commerce and new strategic partnerships, indicating a proactive approach to market expansion and product innovation.
See More
Niagen Bioscience Surpasses 300 Research Agreements, Strengthening NAD+ Research
- Research Agreement Milestone: Niagen Bioscience's external research program has surpassed 300 material transfer agreements (MTAs), marking its leading position in global NAD+ research support and is expected to further enhance the company's influence in the healthy aging sector.
- Clinical Research Outcomes: The program has contributed to the publication of 45 clinical studies, demonstrating the effectiveness and safety of Niagen as an NAD+ booster, thereby enhancing its credibility and competitive edge in the scientific community.
- International Collaboration Expansion: With agreements established with over 200 institutions across 34 countries, the growing global interest in NAD+ biology positions Niagen as a trusted NAD+ booster for researchers, promoting independence and rigor in scientific research.
- Future Research Directions: Niagen Bioscience plans to expand its research into areas such as topical applications and pharmaceutical-grade Niagen intravenous injections, aiming to meet the increasing interest in NAD+ biology and further explore its potential in health and aging.
See More
Niagen Bioscience Increases Share Repurchase Program to $20 Million
- Repurchase Program Expansion: Niagen Bioscience has increased its share repurchase program authorization from $10 million to $20 million, reflecting the company's confidence in its stock value, which is expected to enhance investor sentiment and potentially boost stock performance.
- Repurchase Progress: As of March 17, 2026, the company has repurchased approximately $2.6 million of its common stock under the program, indicating proactive measures to protect shareholder interests amid market fluctuations and reinforcing confidence in its financial health.
- Performance Beats Expectations: Niagen Bioscience reported a GAAP EPS of $0.05, beating estimates by $0.03, and revenue of $33.84 million, exceeding expectations by $2.14 million, demonstrating the company's ability to maintain strong growth in a competitive supplement market.
- Future Growth Targets: The company aims for a revenue growth of 10-15% by 2026 while expanding its injectable product line, indicating strategic decisions focused on product diversification and market share enhancement to further solidify its market position.
See More
Niagen Bioscience Expands Share Repurchase Program to $20 Million
- Program Expansion: Niagen Bioscience has increased its share repurchase program authorization from $10 million to $20 million, reflecting the company's strong confidence in its long-term strategy and value, which is expected to enhance market recognition of its stock.
- Repurchase Progress: As of March 17, 2026, the company has repurchased approximately $2.6 million of its common stock, indicating proactive measures taken to capitalize on market undervaluation, thereby strengthening investor trust.
- Flexibility in Repurchases: The repurchase program is authorized through October 31, 2027, allowing the company to execute buybacks flexibly based on market conditions, potentially through open market transactions or privately negotiated deals, enhancing capital management flexibility.
- Strategic Implications: CEO Rob Fried emphasized that the repurchase program not only reflects confidence in the company's fundamentals but also aims to leverage the disconnect in market valuation of NAGE, thereby creating long-term value for shareholders and further solidifying the company's market position.
See More
Niagen Bioscience to Participate in ROTH Conference
- Management Participation: Niagen Bioscience's senior management will attend the 2026 ROTH Conference, showcasing the company's leadership in healthy aging and likely attracting investor interest while enhancing brand visibility.
- CEO Panel Discussion: CEO Rob Fried will participate in the Technologies Advancing Healthy Aging panel on March 23, with the livestream broadening audience access to the company's innovations in NAD+ science, potentially fostering future investment opportunities.
- One-on-One Investor Meetings: Rob Fried and CFO Ozan Pamir will engage in face-to-face meetings with institutional investors, strengthening relationships with potential investors and driving company financing and market expansion.
- Industry Networking Platform: The conference will gather executives from numerous private and public companies, providing small group discussions and analyst-selected fireside chats, facilitating knowledge sharing and collaboration within the industry, thereby enhancing Niagen's influence in the sector.
See More
Niagen® Expands into Skincare Market with Innovative Product Launch
- Skincare Innovation Lab: Niagen Bioscience has launched the Niagen® Skincare Innovation Lab, aiming to translate its leadership in NAD+ science into skincare innovation, marking the company's entry into the $122.11 billion global skincare market.
- First Product Launch: The inaugural product, Niagen NanoCloud, utilizes a sealed, waterless format to ensure the stability of NAD+ ingredients until use, expected to significantly enhance skincare efficacy and meet consumer demand for effective products.
- Significant Market Potential: Market research indicates that the global anti-aging cosmetics market is projected to reach $106.98 billion by 2035, and Niagen's entry positions it well within the rapidly growing skincare sector, driving future product development.
- Positive Consumer Feedback: A study involving 37 female participants found that consistent use of Niagen NanoCloud resulted in visible skin improvements within two weeks, indicating the product's effectiveness in enhancing skin texture and hydration, thereby strengthening the brand's competitive position in the market.
See More
Niagen Bioscience Reports Q4 and Full-Year 2025 Financial Results
- Financial Performance Overview: Niagen Bioscience reported a Q4 net income of $4.1 million, or $0.05 per share, down from $7.2 million and $0.09 per share in the previous year, indicating challenges in profitability.
- Sales Growth Analysis: Total net sales for Q4 2025 reached $33.84 million, a 16% increase, while full-year sales grew by 30% to $129.4 million, reflecting strong market demand and operational effectiveness.
- Cash Flow Status: As of December 31, 2025, the company had cash and cash equivalents totaling $64.8 million, up from $44.7 million the previous year, enhancing financial stability and capacity for future investments.
- Future Outlook: For 2026, Niagen anticipates a net sales growth of 10-15%, primarily driven by e-commerce and new strategic partnerships, indicating a proactive approach to market expansion and product innovation.
See More
